{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.6","value":"67.9"},{"groupId":"OG001","spread":"19.6","value":"67.8"},{"groupId":"OG002","spread":"26.6","value":"66.9"},{"groupId":"OG003","spread":"18.1","value":"59.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"22"}],"units":"Participants"}],"title":"At baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.5","value":"64.2"},{"groupId":"OG001","spread":"23.4","value":"63.4"},{"groupId":"OG002","spread":"22.4","value":"63.3"},{"groupId":"OG003","spread":"18.9","value":"61.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"17"}],"units":"Participants"}],"title":"At week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.6","value":"64.6"},{"groupId":"OG001","spread":"22.8","value":"61.3"},{"groupId":"OG002","spread":"23.1","value":"56.4"},{"groupId":"OG003","spread":"14.2","value":"67.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"16"}],"units":"Participants"}],"title":"At week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.7","value":"61.8"},{"groupId":"OG001","spread":"21.6","value":"61.5"},{"groupId":"OG002","spread":"21.9","value":"70.4"},{"groupId":"OG003","spread":"14.6","value":"68.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"18"}],"units":"Participants"}],"title":"At week 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.5","value":"65.1"},{"groupId":"OG001","spread":"21.3","value":"69"},{"groupId":"OG002","spread":"21.7","value":"76.9"},{"groupId":"OG003","spread":"18.9","value":"66.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"16"}],"units":"Participants"}],"title":"At week 26"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.3","value":"72.6"},{"groupId":"OG001","spread":"22.4","value":"66.7"},{"groupId":"OG002","spread":"16.5","value":"72.4"},{"groupId":"OG003","spread":"13","value":"70.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"13"}],"units":"Participants"}],"title":"At week 34"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.7","value":"67.3"},{"groupId":"OG001","spread":"23.2","value":"65"},{"groupId":"OG002","spread":"19.5","value":"77.8"},{"groupId":"OG003","spread":"17.1","value":"65.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"title":"At week 42"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.4","value":"72"},{"groupId":"OG001","spread":"18.6","value":"70.8"},{"groupId":"OG002","spread":"19.5","value":"72.2"},{"groupId":"OG003","spread":"17.1","value":"65.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"11"}],"units":"Participants"}],"title":"At week 50"}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"22"}],"units":"Participants"}],"description":"EORTC Quality of Life Lung Cancer Module (QLQ-LC29), Importance of QOL issues assessed using a four-point scale (1 = not at all, 4 = very much) and transformed to a 0-100 score, where higher scores mean worse possible symptom burden or severe impact.","dispersionType":"Standard Deviation","groups":[{"description":"Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab\n\nDurvalumab: Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks","id":"OG000","title":"Experimental Arm for Chemo Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance"},{"description":"Standard Chemotherapy for 4 to 6 cycles, followed by Observation\n\nStandard Chemotherapy: Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation","id":"OG001","title":"Control Arm for Chemo Cohort: Chemotherapy, Then Observation"},{"description":"Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab\n\nDurvalumab: Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks","id":"OG002","title":"Experimental Arm for IO Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance"},{"description":"Ipilimumab every 6 weeks and Nivolumab every 2 or 3 weeks for up to 2 years.\n\nIpilimumab and Nivolumab: Ipilimumab 1 mg/kg every 6 weeks and Nivolumab 360 mg every 3 weeks or 3 mg/kg every 2 weeks for up to 2 years","id":"OG003","title":"Control Arm for IO Cohort: Ipilimumab and Nivolumab"}],"paramType":"MEAN","populationDescription":"The number analyzed for each row reflects the number of participants who completed the question at the corresponding time point.","reportingStatus":"POSTED","timeFrame":"Performed at baseline, then at weeks 6, 12, 18, 26, 34, 42, 50, then every 12 weeks until disease progression and at first progression visit (minimum follow-up is 24 months after randomisation).","title":"Health-Related Quality of Life (QOL): LC29","type":"SECONDARY","unitOfMeasure":"score on a scale"}